LGALS3 and prostate cancer: GR-MD-02 is a complex polysaccharide similar in composition to modified citrus pectin (MCP, GCS-100), a galactose-rich polysaccharide that inhibits Gal-3 binding to endothelial cells, reducing prostate cancer cell viability and enhancing their sensitivity to radiotherapy.